Global DNA Medicine Based on DNA Modification Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global DNA Medicine Based on DNA Modification Market Research Report 2024
Advanced Therapy Based on Gene is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
According to MRAResearch’s new survey, global DNA Medicine Based on DNA Modification market is projected to reach US$ 34850 million in 2033, increasing from US$ 9063 million in 2022, with the CAGR of 20.2% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole DNA Medicine Based on DNA Modification market research.
The advanced therapy based on gene market is driven by the potential to revolutionize healthcare by offering personalized and targeted treatments for genetic disorders and other diseases. Advanced therapy based on gene includes gene therapy, cell therapy, and gene editing techniques, which aim to modify or replace faulty genes to treat or cure diseases at the genetic level. The rise in the understanding of genetic mechanisms and advancements in biotechnology and genetic engineering contribute to market growth as these therapies hold promise for previously untreatable conditions. Moreover, increasing investment in research and clinical trials and the support from regulatory agencies for accelerated approval further boost the development and commercialization of advanced gene therapies. However, the market also faces challenges, including the complexity of manufacturing and delivering gene-based therapies, safety concerns related to viral vectors and off-target effects in gene editing, and high treatment costs. Additionally, addressing regulatory requirements and ensuring accessibility and affordability of advanced gene therapies can pose obstacles for broader adoption. To succeed, companies must focus on research and development to advance the safety and efficacy of gene-based therapies, collaborate with healthcare stakeholders to build robust infrastructure, and address the challenges to fully realize the transformative potential of advanced therapy based on gene in modern medicine.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global DNA Medicine Based on DNA Modification market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Viral
Non-viral
Neurological Diseases
Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The DNA Medicine Based on DNA Modification report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global DNA Medicine Based on DNA Modification market is projected to reach US$ 34850 million in 2033, increasing from US$ 9063 million in 2022, with the CAGR of 20.2% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole DNA Medicine Based on DNA Modification market research.
The advanced therapy based on gene market is driven by the potential to revolutionize healthcare by offering personalized and targeted treatments for genetic disorders and other diseases. Advanced therapy based on gene includes gene therapy, cell therapy, and gene editing techniques, which aim to modify or replace faulty genes to treat or cure diseases at the genetic level. The rise in the understanding of genetic mechanisms and advancements in biotechnology and genetic engineering contribute to market growth as these therapies hold promise for previously untreatable conditions. Moreover, increasing investment in research and clinical trials and the support from regulatory agencies for accelerated approval further boost the development and commercialization of advanced gene therapies. However, the market also faces challenges, including the complexity of manufacturing and delivering gene-based therapies, safety concerns related to viral vectors and off-target effects in gene editing, and high treatment costs. Additionally, addressing regulatory requirements and ensuring accessibility and affordability of advanced gene therapies can pose obstacles for broader adoption. To succeed, companies must focus on research and development to advance the safety and efficacy of gene-based therapies, collaborate with healthcare stakeholders to build robust infrastructure, and address the challenges to fully realize the transformative potential of advanced therapy based on gene in modern medicine.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global DNA Medicine Based on DNA Modification market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Viral
Non-viral
Segment by Application
Neurological Diseases
Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The DNA Medicine Based on DNA Modification report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices